Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Passage Bio Inc has a consensus price target of $25 based on the ratings of 6 analysts. The high is $67 issued by Canaccord Genuity on August 14, 2025. The low is $5 issued by Raymond James on November 14, 2023. The 3 most-recent analyst ratings were released by Chardan Capital, Canaccord Genuity, and Guggenheim on November 12, 2025, August 14, 2025, and August 14, 2025, respectively. With an average price target of $32.67 between Chardan Capital, Canaccord Genuity, and Guggenheim, there's an implied 156.12% upside for Passage Bio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
| Buy Now | Get Alert | ||||||
|---|---|---|---|---|---|---|---|
| 11/12/2025 | Buy Now | 64.65% | Chardan Capital | $6 → $21 | Maintains | Buy | Get Alert |
| 08/14/2025 | Buy Now | 425.3% | Canaccord Genuity | $260 → $67 | Maintains | Buy | Get Alert |
| 08/14/2025 | Buy Now | -21.6% | Guggenheim | $40 → $10 | Maintains | Buy | Get Alert |
| 08/13/2025 | Buy Now | 213.61% | Wedbush | $3 → $40 | Maintains | Outperform | Get Alert |
| 06/24/2025 | Buy Now | -52.96% | Chardan Capital | $6 → $6 | Maintains | Buy | Get Alert |
| 03/04/2025 | Buy Now | -52.96% | Chardan Capital | $7 → $6 | Maintains | Buy | Get Alert |
| 11/29/2024 | Buy Now | -68.64% | Wedbush | → $4 | Assumes | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | -45.12% | Chardan Capital | $7 → $7 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 1.92% | Canaccord Genuity | $13 → $13 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 1.92% | Canaccord Genuity | $13 → $13 | Reiterates | Buy → Buy | Get Alert |
| 09/03/2024 | Buy Now | -45.12% | Rodman & Renshaw | → $7 | Initiates | → Buy | Get Alert |
| 05/15/2024 | Buy Now | 1.92% | Canaccord Genuity | $14 → $13 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 9.76% | Canaccord Genuity | → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/21/2023 | Buy Now | 9.76% | Canaccord Genuity | $8 → $14 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | -60.8% | Raymond James | $9 → $5 | Maintains | Outperform | Get Alert |
| 08/08/2023 | Buy Now | -29.44% | Chardan Capital | $11 → $9 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | -29.44% | Raymond James | $10 → $9 | Maintains | Outperform | Get Alert |
The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on November 12, 2025. The analyst firm set a price target for $21.00 expecting PASG to rise to within 12 months (a possible 64.65% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Passage Bio (NASDAQ:PASG) was provided by Chardan Capital, and Passage Bio maintained their buy rating.
There is no last upgrade for Passage Bio
There is no last downgrade for Passage Bio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Passage Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Passage Bio was filed on November 12, 2025 so you should expect the next rating to be made available sometime around November 12, 2026.
While ratings are subjective and will change, the latest Passage Bio (PASG) rating was a maintained with a price target of $6.00 to $21.00. The current price Passage Bio (PASG) is trading at is $12.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.